Clinical Trial: A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229638) titled 'A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors' on Nov. 13.

Brief Summary: This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors. Phase IB is the dose escalation stage, and Phase II is the efficacy expansion stage.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condi...